IRWD · Ironwood Pharmaceuticals, Inc.

The departure of CFO Gregory Martini, effective May 15, 2026, is not due to any disagreement with the company's financial reporting, suggesting an orderly transition. Ronald Silver, age 44, will serve as interim CFO while retaining his roles as SVP, Corporate Controller and CAO. Silver's extensive tenure at Ironwood since 2018, including roles as Corporate Controller and CAO, provides continuity in financial leadership. His background includes accounting and financial reporting positions at Eze Software Group and RSM LLP. The filing notes no arrangement or family relationship with directors or officers, and no recent transactions with the company, indicating no conflicts of interest. Investors should monitor for a permanent CFO appointment.